Anti-Fibrinolytic Drugs - Dominican Republic

The projected revenue in the Anti-Fibrinolytic Drugs market in the Dominican Republic is expected to reach US$8.58m in 2024.
This market is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 5.66%, leading to a market volume of US$11.30m by 2029.
In comparison to other countries, United States is projected to generate the highest revenue in this market, reaching US$9.86bn in 2024.
The demand for anti-fibrinolytic drugs in the Dominican Republic is steadily increasing due to the rising prevalence of cardiovascular diseases in the country.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Dominican Republic has been experiencing steady growth in recent years.

Customer preferences: Patients in Dominican Republic are increasingly seeking out Anti-Fibrinolytic Drugs due to the rising prevalence of cardiovascular diseases and the increasing awareness of the benefits of these drugs in preventing excessive bleeding during surgery. Additionally, the aging population in the country has led to an increase in demand for these drugs as older individuals are more prone to cardiovascular diseases.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Dominican Republic is the increasing use of these drugs in surgical procedures. As more hospitals and clinics adopt these drugs, the market is expected to continue to grow. Another trend is the introduction of new and more effective Anti-Fibrinolytic Drugs in the market, which has led to increased competition among pharmaceutical companies.

Local special circumstances: The healthcare system in Dominican Republic is still developing, and this has led to challenges in access to healthcare for the population. However, the government has been making efforts to improve the healthcare system, which has led to an increase in the availability of Anti-Fibrinolytic Drugs in the country. Additionally, the high cost of these drugs has been a barrier to access for some patients, but the government has implemented measures to make these drugs more affordable.

Underlying macroeconomic factors: The Dominican Republic has experienced steady economic growth in recent years, which has led to an increase in healthcare spending. This has contributed to the growth of the Anti-Fibrinolytic Drugs market in the country. Additionally, the country has a favorable regulatory environment for pharmaceutical companies, which has led to an increase in investment in the sector.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.